Endotis and Catalent sign anticoagulant deal
This article was originally published in Scrip
Executive Summary
Endotis Pharma and Catalent Pharma Solutions have agreed to develop oral formulations of synthetic oligosaccharide therapeutics. Initially the companies will collaborate on Endotis's indirect factor Xa inhibitor, EP37151, which will begin Phase I clinical trials in the second quarter of next year.